This rule establishes scientifically based guidelines for controlled substance prescribers to co-prescribe an opiate antagonist to a patient pursuant to Section 26B-4-513.

KEY: naloxone, opioid antagonist, co-prescribing

Date of Last Change: November 5, 2023

Notice of Continuation: June 6, 2023

Authorizing, and Implemented or Interpreted Law: 26B-4-513